Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Conditions
Breast Cancer - Bevacizumab - Neoadjuvant Chemotherapy - Molecular Targeted Therapy
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
bevacizumab, neoadjuvant chemotherapy, HER2-negative breast cancer
Study Type
Observational
Study Phase
N/A
Study Design
Time Perspective: Prospective
Intervention
Name: bevacizumab
Type: Drug
Overall Status
Recruiting
Summary
- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- HER2-negative breast cancer patients

- Without surgery

- Plans to neoadjuvant chemotherapy

Exclusion Criteria:

- HER2-positive breast cancer patients

- Post-operative patients
Location
Xijing Hospital , Fourth Military Medical University
Xi`an, Shaanxi, China
Status: Recruiting
Contact: Nanlin Li, Ph.D - +86-186-2963-7041 - nanlin-74@163.com
Start Date
June 2012
Completion Date
September 2014
Sponsors
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Source
Xijing Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page